Employees: 32
Size Qurient (115180.KS) is a South Korea Health Care company (Biotechnology) with a market value of $452M, the 372nd largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩13,030 on 18 Nov 2026.
Performance Over six months the shares fell 56.5%, against -1.8% for the median peer and -37.2% for the South Korea market (cap-weighted) — lowest of 19 in its peer set.
Growth Revenue fell 13.8% over the last twelve months (peer median +5.0%); the operating margin is -511.6% (peer median -4.1%).
Valuation It trades at 84.4× enterprise value to sales against a peer median of 6.4× (2nd most expensive of 14).
Capital Return on invested capital runs 187.4 points below its cost of capital (5.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩7.13B | ₩6.98B | ₩9.18B | ₩9.03B | ₩8.47B |
| Revenue growth | — | -24% | +2% | +7% | — |
| Gross profit | -₩751M | -₩31.4M | ₩496M | ₩944M | ₩1.06B |
| EBITDA | -₩35.0B | -₩28.5B | -₩26.6B | -₩22.4B | -₩26.8B |
| Net income | -₩38.7B | -₩30.1B | -₩23.6B | -₩21.1B | -₩25.5B |
| Free cash flow | -₩36.3B | -₩27.5B | -₩22.1B | n/a | -₩24.2B |
| Capital expenditure | ₩158M | ₩3.70B | ₩83.7M | ₩101M | ₩519M |
| Total debt | ₩1.00B | ₩12.7B | ₩841M | ₩334M | ₩807M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 115180.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -34.9% | -7.3% | lowest of 21 |
| 6-month return | -56.5% | -1.8% | lowest of 19 |
| Distance from 52-week high | -79.3% | -37.5% | 2nd lowest of 21 |
| Revenue growth (TTM) | -13.8% | +5.0% | 3rd lowest of 16 |
| Operating margin | -511.6% | -4.1% | 2nd lowest of 15 |
| EV / Sales | 84.4× | 6.4× | 2nd most expensive of 14 |
| ROIC minus cost of capital | -187.4 pp | -6.0 pp | lowest of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Qurient 115180.KS | South Korea | $452M | -56% | -14% | -512% | 84.4× | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $454M | -2% | -6% | -1% | 11.8× | n/a | n/a |
| Shattuck Labs STTK | United States | $455M | -28% | -100% | n/a | n/a | n/a | n/a |
| EirGenix 6589.TW | Taiwan | $444M | +15% | +58% | -51% | 9.9× | n/a | n/a |
| Arvinas ARVN | United States | $443M | -26% | -12% | -10% | n/a | n/a | n/a |
| HanchorBio 7827.TW | Taiwan | $462M | n/a | n/a | -4,673% | 509.6× | n/a | n/a |
| DiaMedica Therapeutics DMAC | United States | $463M | +50% | n/a | n/a | n/a | n/a | n/a |
| IRulya Therapeutics IRLA | United States | $440M | +88% | n/a | n/a | n/a | n/a | n/a |
| Berry Genomics 000710.SZ | China | $439M | -17% | -2% | -24% | 3.3× | n/a | n/a |
| Kamada KMDA | United States | $465M | +3% | +5% | 15% | 2.0× | 5.0% | +6.5% |
| Qingdao Vland Biotech 603739.SS | China | $437M | -24% | +5% | 7% | 2.2× | 7.7% | +7.3% |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $470M | n/a | n/a | n/a | n/a | n/a | n/a |
| Scinopharm Taiwan 1789.TW | Taiwan | $435M | -2% | -5% | -4% | 4.0× | 2.1% | +0.5% |
| Fennec Pharmaceuticals FENC | United States | $471M | +37% | +71% | 5% | 6.4× | 58.8% | +204.7% |
| Prothena PRTA | United States | $429M | -11% | +347% | -73% | 3.1× | n/a | n/a |
| Qyuns Therapeutics 2509.HK | Hong Kong | $428M | -11% | +230% | 56% | 2.6× | -19.5% | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $427M | +11% | +13% | 47% | 12.3× | 5.3% | +70.5% |
| Neurogene NGNE | United States | $479M | -14% | -100% | n/a | n/a | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +9% | n/a | n/a | n/a | n/a | n/a |
| TaiMed Biologics 4147.TWO | Taiwan | $480M | +19% | +7% | -31% | 22.7× | n/a | n/a |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $424M | -8% | +44% | -5% | 14.6× | n/a | n/a |